Contact
Privacy Policy

Copyright © DEEPNOID Inc. All rights reserved.

Back to list
Medical AI

DEEPNOID’s Cerebral Aneurysm AI Solution Becomes the First to Receive a Provisional Listing Fee under National Health Insurance, Enabling Non-Reimbursable Billing

November 1, 2024
DEEPNOID’s Cerebral Aneurysm AI Solution Becomes the First to Receive a Provisional Listing Fee under National Health Insurance, Enabling Non-Reimbursable Billing

- The first cerebral aneurysm AI solution in Korea to enter the non-reimbursable market, demonstrating its efficiency and clinical utility
- Provisional listing makes patients eligible for private insurance coverage and is expected to secure stable long-term revenue

DEEP:NEURO, the AI-based diagnostic assistance solution for cerebral aneurysms developed by DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), has obtained a non-reimbursable billing code. Hospitals can now bill patients for the service, and patients can claim the cost through their private indemnity health insurance.
The provisional listing of DEEP:NEURO, which makes the service eligible for private insurance coverage, is also expected to help secure stable revenue. Hospitals receive payment from patients, who pay for the service first and can then recover part of the cost through private indemnity health insurance.
DEEPNOID also expects demand for brain MRA scans to drive revenue growth. A ruptured cerebral aneurysm can lead to disability, lasting complications, or even death, but not every aneurysm requires surgery. Depending on the case, an aneurysm may be managed through follow-up monitoring or treated non-surgically. Patients therefore undergo regular MRA scans to track changes in the aneurysm and the effects of treatment.
“We expect this provisional listing to boost our entry into overseas markets,” said Hyun Seok Choi, Chief Medical Officer of DEEPNOID. “It will have a positive effect on the joint research and business partnerships we are discussing in Singapore, Taiwan, Japan, and other countries, and will give momentum to our international business.”
“The provisional listing of DEEP:NEURO not only recognizes its clinical value but will also serve as an important foundation for revenue growth,” said Woo Sik Choi, CEO of DEEPNOID. “With this listing, we expect more hospitals to adopt DEEP:NEURO. Building on this momentum, we will expand the clinical application of our AI solutions and continue to deliver innovation that creates real value in clinical practice.”
DEEP:NEURO entered the clinical market in 2023 after being designated as an Innovative Medical Technology. It has been adopted by 29 hospitals to date, and DEEPNOID expects the provisional listing to further increase the number of hospitals using the solution, leading to stable revenue.

###